Welcome back to the Class Action & MDL Roundup! This edition covers notable class actions from the second quarter of 2022.
In this edition, fail-safe classes fail, consumers smoke a motion to dismiss, and you can’t bring it if you don’t know whodunit. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
We wrap up the Roundup with a summary of class action settlements finalized in the second quarter.
Class Action MDL Roundup
October 13, 2022
Class Action & MDL Roundup 2022 Q2: Directing physical loss and damage
- Cari K. Dawson
- David Venderbush
- Ryan P. Ethridge
- David Carpenter
- F. Nicholas Chandler
- Sean R. Crain
- Jamie S. George
- Bradley Harder
- Michelle Jackson
- Jyoti Jindal Kottamasu
- Laura A. Komarek
- Matthew D. Lawson
- Andrew J. Liebler
- William J. Repko III
- Noelle Reyes
- Jason Rottner
- Troy A. Stram
- Ellie Saathoff
- Andrew T. Sumner
- Amanda M. Waide
- Nick A. Young
Meet the Authors
Senior Associate
Phone:
+1 404 881 7969
Other Phone:
+1 212 905 9156
Email:
nick.chandler@alston.com
Related News & Insights
-
Class Action MDL Roundup September 29, 2023Class Action & MDL Roundup 2023 Q2 – Ascertainability lives!In the latest edition of the Class Action & MDL Roundup, covering notable class actions from the second quarter of 2023, essential oils may need therapy, an ever-growing library goes nowhere, and one exclusion is specifically ambiguous. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup June 30, 2023Class Action & MDL Roundup 2023 Q1 – We don’t discount confidentialityIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the first quarter of 2023, in pork we antitrust, paid time off is not pay, and if it’s free, it won’t cost you a TCPA violation. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup March 27, 2023Class Action & MDL Roundup 2022 Q4 – A “healthy” dose of litigationIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the fourth quarter of 2022, class actions gain an international flair, insurers have cures for COVID cases, and a remote presence is still a presence. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup December 20, 2022Class Action & MDL Roundup 2022 Q3 – The very definition of all naturalIn the latest edition of the Class Action & MDL Roundup, covering notable class actions from the third quarter of 2022, all dog stairs go to heaven, the Third Circuit resets Article III standing, and challenging damages can be aggregating. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
-
Class Action MDL Roundup July 13, 2022Class Action & MDL Roundup – Q1 2022In the latest edition of the Class Action & MDL Roundup, covering notable class actions from the first quarter of 2022, COVID cases are still endemic for insurance companies, kids’ contracts are voidable but not void, and crypto can’t escape the Securities Act. Plus, we have our usual coverage of lawsuits over drugs and pharmaceuticals, wage-and-hour rules, shareholder losses, and more.
Media Contact